Having gained approval for pancreatic cancer treatment, we have suggested that the mTOR inhibitor Rapamycin could be adopted as a potential treatment regimen for oral cancer patients due to its promising effects. The gene discussed is MTOR; the disease is lip and oral cavity carcinoma.